22.98

1.06% 0.24

Tandem Diabetes Care Inc (TNDM)

Overview News Price History Option Chain Financials Why TNDM Down? Discussions Forecast Stock Split

Tandem Diabetes Care Inc stock is traded at $22.98, with a volume of 1.04M. It is up +1.06% in the last 24 hours and up +30.49% over the past month. Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.

Previous Close:

$22.74

Open:

$22.89

24h Volume:

1.04M

Relative Volume:

0.60

Market Cap:

$1.43B

Revenue:

$796.00M

Net Income/Loss:

$-136.49M

P/E Ratio:

-11.00

EPS:

-2.09

Net Cash Flow:

$-64.24M

1W Performance:

+6.98%

1M Performance:

+30.49%

6M Performance:

-24.90%

1Y Performance:

-47.83%

1-Day Range:

$22.77

$23.54

1-Week Range:

$20.86

$23.54

52-Week Range:

$15.75

$53.69

Tandem Diabetes Care Inc Stock (TNDM) Company Profile

Name

Tandem Diabetes Care Inc

Sector

Healthcare (1153)

Industry

Medical Devices (157)

Phone

858-366-6900

Address

12400 HIGH BLUFF DRIVE, San Diego, CA

Employee

2,650

Twitter

@tandemdiabetes

Next Earnings Date

2024-11-06

Latest SEC Filings

TNDM's Discussions on Twitter

Compare TNDM with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TNDM Tandem Diabetes Care Inc	22.98	1.43B	796.00M	-136.49M	-64.24M	-2.09
ABT Abbott Laboratories	133.24	231.09B	42.34B	13.50B	6.66B	7.71
BSX Boston Scientific Corp	102.86	155.24B	17.55B	2.03B	2.72B	1.37
SYK Stryker Corp	380.92	144.54B	23.22B	2.86B	3.58B	7.40
MDT Medtronic Plc	83.48	108.82B	33.20B	4.26B	5.47B	3.29
EW Edwards Lifesciences Corp	73.68	44.31B	5.54B	4.18B	623.10M	7.00

Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-10-25	Initiated	Mizuho	Neutral
Mar-05-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Mar-04-25	Downgrade	Citigroup	Buy → Neutral
Mar-03-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Feb-28-25	Downgrade	Bernstein	Outperform → Mkt Perform
Dec-02-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-06-24	Initiated	Bernstein	Outperform
Oct-04-24	Initiated	Goldman	Neutral
Oct-02-24	Initiated	RBC Capital Mkts	Outperform
Aug-22-24	Initiated	Morgan Stanley	Equal-Weight
Aug-08-24	Initiated	Canaccord Genuity	Buy
May-30-24	Initiated	Redburn Atlantic	Buy
May-22-24	Upgrade	Citigroup	Neutral → Buy
Apr-29-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Apr-25-24	Upgrade	Leerink Partners	Market Perform → Outperform
Mar-26-24	Upgrade	Stifel	Hold → Buy
Aug-04-23	Downgrade	Citigroup	Buy → Neutral
May-05-23	Downgrade	BofA Securities	Neutral → Underperform
Apr-24-23	Downgrade	Raymond James	Outperform → Mkt Perform
Mar-29-23	Initiated	UBS	Neutral
Jan-26-23	Initiated	Wolfe Research	Peer Perform
Nov-15-22	Upgrade	Wells Fargo	Underweight → Equal Weight
Oct-18-22	Initiated	Barclays	Overweight
Oct-12-22	Initiated	Jefferies	Buy
Aug-09-22	Downgrade	Wells Fargo	Overweight → Underweight
Mar-02-22	Resumed	BofA Securities	Neutral
Jan-19-22	Upgrade	Wells Fargo	Equal Weight → Overweight
Jul-21-21	Resumed	Cowen	Outperform
May-25-21	Initiated	Barclays	Underweight
Dec-15-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Aug-20-20	Initiated	Wells Fargo	Overweight
Jul-31-20	Upgrade	Guggenheim	Neutral → Buy
Jul-06-20	Upgrade	Citigroup	Neutral → Buy
Jun-18-20	Reiterated	Raymond James	Outperform
Apr-24-20	Downgrade	SVB Leerink	Outperform → Mkt Perform
Mar-23-20	Downgrade	Guggenheim	Buy → Neutral
Mar-05-20	Initiated	Citigroup	Neutral
Feb-06-20	Initiated	Raymond James	Outperform
Feb-04-20	Downgrade	Robert W. Baird	Outperform → Neutral
Oct-18-19	Initiated	Guggenheim	Buy
Oct-04-19	Upgrade	UBS	Neutral → Buy
May-17-19	Reiterated	BofA/Merrill	Neutral
May-13-19	Initiated	SVB Leerink	Outperform
Mar-08-19	Initiated	BMO Capital Markets	Outperform
Mar-05-19	Reiterated	BofA/Merrill	Neutral
Feb-27-19	Reiterated	Lake Street	Buy
Nov-21-18	Upgrade	Robert W. Baird	Neutral → Outperform
Sep-26-18	Reiterated	Dougherty & Company	Buy
Sep-26-18	Reiterated	Piper Jaffray	Overweight

View All

Tandem Diabetes Care Inc Stock (TNDM) Latest News

May 09, 2025

INVESTOR ALERT: Levi & Korsinsky Notifies Tandem Diabetes Care, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – TNDM - ACCESS Newswire

May 09, 2025

INVESTOR ALERT: Levi & Korsinsky Notifies Tandem Diabetes Care, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineTNDM - ACCESS Newswire

May 09, 2025

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Tandem Diabetes Care, Inc.(TNDM) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

May 09, 2025

INVESTOR ALERT: Levi & Korsinsky Reminds Tandem Diabetes Care, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 7, 2023TNDM - ACCESS Newswire

May 09, 2025

INVESTOR ALERT: Levi & Korsinsky Reminds Tandem Diabetes Care, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 7, 2023 – TNDM - ACCESS Newswire

May 09, 2025

May 07, 2025

Earnings Release: Here's Why Analysts Cut Their Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Price Target To US$35.52 - simplywall.st

May 03, 2025

Tandem Diabetes jumps as overseas sales drive Q1 beat - MSN

May 03, 2025

May 02, 2025